AMENDMENTS TO THE CLAIMS

Please amend claims 1-2, 4, 7, and 9-14 as set forth below.

Please cancel claims 3 and 8 without prejudice or disclaimer.

Please add new claims 15-25 as set forth below.

The listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) An isolated compound having the structure (I):



(I)

wherein:

R_1 ~~to R_3 are each independently H, alkyl,~~ is a substituted alkyl~~, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl~~;

R_2 is methyl;

R_3 is hydroxy;

Each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

E_1 ~~to~~, E_3, and E_4 are ~~each independently~~ ~~-O, -NR$_5$, or -S, wherein R$_5$ is H or C$_1$-C$_6$ alkyl~~;

E_2 is $-NR_5$, wherein R_5 is –H or C_1-C_6 alkyl; and

X is 0 to 8 [[;]] ,

~~, with the proviso that isolated compound does not have the structure of compound (VI).~~



~~(VI)~~

2. (Currently Amended) The compound of Claim 1, wherein ~~E_1, E_3, and E_4 are -O, and~~ E_2 is -NH.

3. (Canceled).

4. (Currently Amended) The compound of Claim 1, wherein R_1 is a substituted alkyl substituted with one or more substitutions selected from halogen, cyano, oxyacyl, amino, amido, -C(O)H, acyl, carboxyl, and sulfonamide.

5. (Original) The compound of Claim 4, wherein the substituted alkyl is a halogenated alkyl.

6. (Original) The compound of Claim 5, wherein the halogenated alkyl is a chlorinated alkyl.

7. (Currently Amended) A pharmaceutical composition comprising at least one compound of Claim 1 in a pharmaceutically acceptable carrier ~~therefor~~ thereof.

8. (Canceled).

9. (Currently Amended) The pharmaceutical composition of Claim [[8]] 7, further comprising at least one additional anti-neoplastic agent.

10. (Currently Amended) A method of treating a ~~mammalian cell proliferative disorder~~ refractile mammalian cancer cell, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure (I):



(I)

wherein:

R_1 to R_3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, ~~sulfonyl,~~ sulfonamide, or sulfuryl;

Each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

E_1 to E_4 are each independently -O,- NR_5, or -S, wherein R_5 is -H or C_1-C_6 alkyl; and

X is 0 to 8 [[;]] .

~~thereby treating a mammalian cell proliferative disorder, with the proviso that the compound does not have the structure of compound (VI).~~



~~(VI)~~

11. (Currently Amended) The method of Claim 10, wherein the refractile mammalian cancer cell is human.

12. (Currently Amended) The method of Claim 10, wherein ~~the disorder is characterized by the formation of a neoplasm~~ compound has the structure of formula (V):



13. (Currently Amended) The method of Claim [[12]] 10, wherein the ~~neoplasm~~ refractile cancer cell is selected from the group consisting of a mammary cancer cell, a small-cell lung cancer cell, a non-small-cell lung cancer cell, a colorectal cancer cell, a leukemia cancer cell, a melanoma cancer cell, a pancreatic adenocarcinoma cancer cell, a central nervous system (CNS) cancer cell, an ovarian cancer cell, a prostate cancer cell, a sarcoma cell of a soft tissue cancer, [[or]] a sarcoma cell of a bone, a head cancer cell, ~~and~~ a neck cancer cell, a gastric ~~which includes~~ cancer cell, a thyroid ~~an non-Hodgkin's disease~~ cancer cell, a stomach cancer cell, a myeloma cancer cell, a bladder cancer cell, a renal cancer cell, a neuroendocrine cancer cell, ~~which includes thyroid and~~ a non-Hodgkin's cancer disease cell and a Hodgkin's disease ~~neoplasms~~ cancer cell.

14. (Currently Amended) The method of Claim [[12]] 13, wherein the ~~neoplasm~~ refractile cancer cell is a ~~colorectal neoplasm~~ sarcoma cell of a soft tissue or a sarcoma cell of a bone.

15. (New) The method of Claim 13, wherein the refractile cancer cell is a leukemia cancer cell.

16. (New) The method of Claim 13, wherein the refractile cancer cell is a myeloma cancer cell.

17. (New) The method of Claim 13, wherein the refractile cancer cell is an ovarian cancer cell.

18. (New) The method of Claim 13, wherein the refractile cancer cell is a prostate cancer cell.

19. (New) The method of Claim 13, wherein the refractile cancer cell is a non-Hodgkin's disease cancer cell.

20. (New) The method of Claim 13, wherein the refractile cancer cell is a pancreatic adenocarcinoma cancer cell.

21. (New) The method of Claim 10, wherein: R_1 is a substituted alkyl; R_2 is methyl; R_3 is hydroxy; each R_4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl; E_1, E_4 and E_3 are -O; E_2 is $-NR_5$, wherein R_5 is –H or C_1-C_6 alkyl; and X is 0 to 8.

22. (New) The method of Claim 21, wherein R_1 is a halogenated alkyl.

23. (New) The method of Claim 10, further comprising administering at least one additional anti-neoplastic agent.

24. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound having the structure:



,

wherein the pharmaceutical composition is in a solid form.

25. (New) The compound of Claim 1, wherein the structure is:



.